The efficacy results of UDCA on NAFLD/NASH have been mixed, with some trials showing improvement in ALT and other histological markers such as steatosis, inflammation, and fibrosis [76, 154, 155], while others show no significant difference when compared to placebo [156–158]. This evidence concerns the gene GPT and steatosis.